A 28-year-old woman with Guillain-Barré Syndrome is compared with a patient with chronic inflammatory demyelinating polyneuropathy (CIDP). Which feature most reliably distinguishes GBS from CIDP?

Explanation

## GBS vs. CIDP: The Critical Discriminator ### Time Course as the Gold Standard **Key Point:** The **time course of progression** is the single most reliable feature distinguishing GBS from CIDP: - **GBS:** Reaches nadir (maximum weakness) within **4 weeks** (typically 1–2 weeks), then plateaus or improves. - **CIDP:** Progressive or relapsing course over **>8 weeks** (by definition, ≥8 weeks for diagnosis). This temporal distinction is encoded in the diagnostic criteria for both conditions. ### Comparative Table | Feature | Guillain-Barré Syndrome | CIDP | |---------|-------------------------|------| | **Time to nadir** | **≤4 weeks** | **>8 weeks** (progressive/relapsing) | | **Progression pattern** | Monophasic, rapid | Chronic, relapsing-remitting or progressive | | **NCS findings** | Demyelination (early) | Demyelination (consistent) | | **CSF protein** | Elevated (80–500 mg/dL) | Elevated (often >100 mg/dL) | | **Reflexes** | Areflexia (early) | Areflexia (variable) | | **Recovery** | Spontaneous, over weeks–months | Requires immunotherapy; may relapse | | **Immunotherapy response** | IVIG/PE effective acutely | IVIG/PE/corticosteroids needed chronically | ### Why Time Course Is the Discriminator **High-Yield:** The **4-week cutoff** is the cardinal diagnostic criterion. GBS is acute and self-limited (though severe); CIDP is chronic and relapsing. A patient with progressive weakness at 12 weeks is CIDP, not GBS, regardless of other features. **Clinical Pearl:** GBS patients often improve spontaneously after reaching nadir, even without treatment. CIDP patients require long-term immunotherapy and may relapse repeatedly. This prognostic difference is critical for management. ### Mnemonic **GBS = "Get Better Soon" (≤4 weeks); CIDP = "Chronic In Dips" (>8 weeks, relapsing)** --- ## Why Each Distractor Is Misleading - **Demyelinating pattern on NCS:** Both GBS and CIDP show demyelination on nerve conduction studies. Demyelination is NOT discriminating; both are demyelinating conditions. - **Elevated CSF protein:** Both GBS and CIDP have elevated CSF protein. This is a shared feature, not a discriminator. - **Symmetric ascending paralysis:** Both conditions present with symmetric ascending paralysis. This clinical pattern is common to both and does not distinguish them.